Subscribe To
Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol
Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparse...
November 3, 2023, 2:46 pm
Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan...
October 13, 2023, 8:30 pm
Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsenta...
October 13, 2023, 4:30 pm
China has placed the chairman of troubled property firm evergrande 'under police control'
Bloomberg with the info citing unnamed sources.Details are sparse:China Evergrande's billionaire chairm...
September 27, 2023, 3:05 am
Travere therapeutics to present abstracts at the 17th international symposium on iga nephropathy (iigann 2023)
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will pr...
September 26, 2023, 4:30 pm
Nzd/usd pressured amid subdued conditions, below 0.6000
The upcoming week features sparse New Zealand economic data but includes the RBA monetary policy meetin...
September 4, 2023, 3:44 pm
Yen staying weak in muted trading, chinese yuan softens
Trading in the forex market today saw a tempered tone, with most major currencies trading in a tight range due to a ...
August 28, 2023, 12:56 pm
Economic calendar in asia for thursday, 24 august 2023 is nearly empty
The only item on the calendar is the regular weekly International Transactions in Securities data from Japan. Even into Europe/UK time its ...
August 23, 2023, 8:42 pm
Vicor: valuations say 'sell'
Vicor Corp. has doubled off its recent lows, but the stock's valuation now appears to be stretched. The company beat top and bottom line expectations ...
August 8, 2023, 2:12 pm
News explorer — sparse news extends streak of underwhelming bitcoin and ethereum prices
Read the latest Bitcoin and Ethereum news from Decrypt. Get the latest on cryptocurrency prices, breaking news, and more about Bitcoin and blockchain....
August 5, 2023, 6:14 pm
This week in coins: sparse news extends streak of underwhelming bitcoin and ethereum prices
Only one of the top thirty cryptocurrencies by market cap posted notable gains: Dogecoin rival Shiba Inu (SHIB), up 14.7% for the week. Read Full Stor...
August 5, 2023, 3:59 pm
Gbp/usd surges amidst us labor market data, boe rate hike bets
BoE anticipated rate hike cushions GBP amid sparse economic data. The post GBP/USD surges amidst US lab...
June 8, 2023, 6:59 pm
Why progyny caught my eye; is it a buy?
sparsely followed Progyny, Inc. is quietly making industry waves. The target market is in its infant st...
May 16, 2023, 9:10 am
Travere therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug
Travere Therapeutics Inc.'s stock TVTX tumbled 35% Tuesday, after the company said data from a two-year study of a kidney drug failed to show a statis...
May 2, 2023, 12:50 pm
Travere therapeutics announces topline results from two-year primary efficacy endpoint in pivotal phase 3 duplex study of sparsentan in focal segmental glomerulosclerosis
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints tren...
May 1, 2023, 8:05 pm
Economic calendar in asia - a very light one
A sparse data agenda today - just one item of note, data from the Bank of Japan:Corporate Service Price...
April 24, 2023, 8:15 pm
Merck's prometheus acquisition is a step in the right direction
Merck is facing the LOE on Keytruda before the end of the decade, which makes up more than 35% of the company's revenue. The company has an impressive...
April 17, 2023, 12:09 pm
Travere therapeutics announces interim analysis from the phase 3 protect study of filspari™ (sparsentan) in iga nephropathy published in the lancet and presented at world congress of nephrology 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control SAN DIEGO, April 01, 202...
April 1, 2023, 8:30 am
Chinook: travere's sparsentan approval is net positive
Travere's FILSPARI (sparsentan) received accelerated approval for IgAN's disease on Feb 17, 2023. Chino...
February 22, 2023, 2:26 am
Travere: multiple catalysts stacking
There are other powerful catalysts brewing in the pipeline that would deliver leaping sales growth in the coming years. ...
February 14, 2023, 9:54 am